Fortis Healthcare Limited

rs,

tement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in India

31.1%

Issue”), subject to approval of the shareholders and other regulatory approvals which constituted 31.1% share capital of the Company. The shareholders of the Company approved the Preferential Issue by r

0.77%

subsequent to which the shareholding of the erstwhile Promoter Group in the Company was reduced to 0.77%. In terms of agreements dated September 30, 2017, FHsL assigned the outstanding ICDs to a third pa

71%

ubsidiary (i.e. Escorts Heart Institute and Research Centre Limited (“EHIRCL’)), purchased further 71% equity interest in Fortis Healthstaff Limited(“Healthstaff’) at an aggregate consideration of Rupe

29%

while promoter group company. EHIRCL also could not directly takeover the loan, as EHIRCL (holding 29%) could not have taken over the burden of the entire debt of Healthstaff. Therefore, a way to help

51%

18, the Company through its subsidiary (i.e. Fortis Hospitals Limited ("FHsL’)), purchased further 51% equity interest in Fortis Emergency Services Limited (FESL) at an aggregate consideration of Rupee

49%

as not in promoter group company. FHsL also could not directly takeover the loan, as FHsL (holding 49%) could not have taken over the burden of the entire debt of FESL. Therefore, this transaction was

100%

ear 2014-15, the Company through its subsidiary (i.e. Fortis Hospitals Limited (“FHsL’)), acquired 100% stake in Birdie & Birdie Realtors Pvt; Ltd. (“Birdie”) from certain persons related to the erstwhil

14%

he erstwhile promoters, wherein Rupees 12,275 lacs were paid towards ICDs at a rate of interest of 14% per annum and Rupees 7,725 lacs were paid for the shares acquired. The total enterprise value of B

10%

March 31, 2018, investments held in the Global Dynamic Opportunity Fund were sold at a discount of 10%. (ix) (D) There is no further finding in additional procedures/enquiries by independent exper

473 Crore

1992 to furnish certain information and documents relating to the short-term investments of Rupees 473 Crores reported in the media. SEBI had appointed forensic auditors to conduct a forensic audit, of colla

INR 397.12 Crore

w.r.t SCN -1 and directed the Company & FHsL to pursue the measures taken to recover the amount of INR 397.12 Crores (approx.) along with the interest from erstwhile Promoters; & Audit Committee to regularly monito

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“In the aforesaid context, proper and sufficient care has also been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities on a going forward basis.”

“Based on the external legal counsel advice, the Company believes that EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the unaudited Consolidated Financial Results.”

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“• Net debt to EBITDA was at 0.41x vs 0.53x (basis annualized EBITDA of Q3FY23 & annualized EBITDA Q3FY22, respectively) PERFORMANCE REVIEW HOSPITALS BUSINESS STRENGTHENING MEDICAL INFRASTRUCTURE • During the quarter, Fortis commenced an Electronic Medical Record (EMR) implementation project.”

“• • The Fortis EMR project would consist of an initial Discovery phase, followed by solution Analysis and Customization, followed by a pan-Fortis rollout across network hospitals, in a phased manner.”

“• The Company commenced its EMR (Electronic Medical Records) implementation project.”

Registered Office

2

Matters in relation to Regulatory Authorities

2

Cash

2

Fax

1

Parent

1

Subsidiaries

1

Joint ventures

1

Associates

1

For further details please contact

1

Fax

Limited Review Report on unaudited standalone financial results of Fortis Healthcare Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Fortis Healthcare Limited 1. Wehave reviewed the accompanying Statement of unaudited standalone financial results of Fortis Healthcare Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 (“the Statement”). 2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescrib

Registered Office

BSR&Co. LLP Limited Review Report (Continued) Fortis Healthcare Limited b. Note 4 of the Statement relating to the order dated 22 September 2022 of the Hon’ble Supreme Court whereby it has directed the Hon'ble High Court of Delhi inter alia that it may also consider issuing appropriate process and appointing forensic auditor(s) to analyse the transactions entered into between the Company and RHT Health Trust and other related transactions. The above mentioned Note also states that the Hon’ble Supreme Court has observed that prima facie, it appears to be acquisition of proprietary interest of RHT Health Trust by the Company are to subserve the business structure of the Company. Our conclusion is not modified in respect of the above matters. ForBSR &Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 \ Se ps _ Rajesh Arora Partner Membership No.: 076124 UDIN:23076124BGZBHR5049 Gurugram 10 February 2023 FORTIS HEALTHCARE LIMITED CIN: L85110PB1996PLC045933 Fortis Hospita

Matters in relation to Regulatory Authorities

(a) Inthe above backdrop, during financial year 2017-18 the Company received a communication from the Securities and Exchange Board of India (SEBI), confirming that an investigation has been instituted by SEBI in the matter of the Company. In the aforesaid letter, SEB! required the Company under section 11C (3) of the SEBI Act, 1992 to furnish certain information and documents relating to the short-term investments of Rupees 473 Crores reported in the media. SEBI had appointed forensic auditors to conduct a forensic audit, of collating information from the its subsidiaries furnished requisite information and Company and certain of its subsidiaries. The Company / documents requested by SEBI. In furtherance of the above, subsequently on October 17, 2018 SEBI passed an ex-parte Interim Order (“Order”) whereby it observed that certain transactions were structured by some identified entities over a certain duration, and undertaken through the Company, which were prima facie fictitious and f

Subsidiaries

(i) Escorts Heart Institute and Research Centre Limited (“EHIRCL") (ii) Fortis Hospitals Limited (iii) Fortis Asia Healthcare Pte Limited (iv) Fortis Healthcare International Limited (v) Fortis Global Healthcare (Mauritius) Limited (vi) Fortis Malar Hospitals Limited (vii) Malar Stars Medicare Limited (viii) Fortis Health Staff Limited \ 2

Registered Office

BSR& Co {apartnership firm with RegistrationNe BAG1223) convertedinto 8 SR & Co LLP (a Limited Liability Partnership with LLP Registration Na AAB-8181) with effect fram Octaber 14, 2013 14th Floor, Central B Wing and Narth C Wing, Nesca IT Park 4, Nesco Center, Western Express Highway, Garegaan (East), Mumbai - 400063 Limited Review Report (Continued) Fortis Healthcare Limited BSR&Co. LLP (ix) Fortis Cancer Care Limited (x) Fortis La Femme Limited (xi) Fortis Health Management (East) Limited (xii) Hiranandani Healthcare Private Limited (xiii) SRL Limited (xiv) SRL Diagnostics Private Limited (xv) SRL Reach Limited (xvi) SRL Diagnostics FZ- LLC (xvii) Fortis Healthcare International Pte Limited (‘FHIPL’) (xviii) Birdie and Birdie Realtors Private Limited (xix) Stellant Capital Advisory Services Private Limited (xx) RHT Health Trust Manager Pte Limited (xxi) Fortis Emergency Services Limited (xxii) Fortis Hospotel Limited (xxiii) Escort Heart and Super Speciality Hospital Limited (xxiv)

Joint ventures

(i) Fortis Cauvery (ii) Fortis C- Doc Healthcare Limited (iii) SRL Diagnostics (Nepal) Private Limited